Emerging therapeutic avenues in cardiac amyloidosis

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Cardiac Amyloidosis (CA) is a toxic infiltrative cardiomyopathy caused by amyloid fiber deposition in the myocardium.
• This leads to severe complications including ventricular dysfunction, diastolic dysfunction, and arrhythmias, ultimately progressing to heart failure.
• Key types include immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), with ATTRwt and ATTRv having significant prevalence.

Purpose of the Study:

• To review the current status of emerging therapeutic agents for cardiac amyloidosis currently in clinical trials.
• To highlight advancements in understanding the pathophysiology and mechanistic pathways of AL and ATTR amyloidosis.
• To discuss the potential of new therapeutic approaches and agents with improved efficacy and safety profiles.

Main Methods:

• Literature review of recent pathological findings and therapeutic approaches for cardiac amyloidosis.
• Analysis of emerging therapeutic agents in clinical trials for AL and ATTR cardiac amyloidosis.
• Focus on the pathophysiology of amyloid fiber formation and triggered mechanistic pathways.

Main Results:

• Established therapies for AL amyloidosis include melphalan and bortezomib. Tafamidis is the standard for ATTR amyloidosis.
• Emerging therapeutic agents in clinical trials demonstrate potent and rapid effects.
• These new agents exhibit a favorable safety profile compared to older treatments.

Conclusions:

• Significant progress has been made in understanding and treating cardiac amyloidosis.
• Emerging therapies offer new hope for patients with both AL and ATTR types of the disease.
• Ongoing clinical trials are crucial for validating these novel therapeutic agents.